Yi Yooni A, Rozanski Alexander T, Shakir Nabeel A, Viers Boyd R, Ward Ellen E, Bergeson Rachel L, Morey Allen F
Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA.
Transl Androl Urol. 2020 Feb;9(1):3-9. doi: 10.21037/tau.2019.08.03.
The optimal management strategy for recurrent urethral stricture disease (USD) following urethroplasty remains undefined. We aim to evaluate the role and efficacy of endoscopic urethral balloon dilation in temporizing recurrent USD after failed urethroplasty.
Between 2007-2018 at our institution, 80 patients underwent balloon dilation procedures for bulbomembranous urethral strictures. Balloon dilation was performed with an 8-cm, 24-French UroMax Ultra™ balloon dilator, under direct vision, guided by a 16-French flexible cystoscope. Patients who underwent concomitant open or endoscopic urethral procedures were excluded. Treatment failure was defined as the need for subsequent surgical intervention for stricture recurrence. Stricture characteristics including etiology, length, location, severity stage, and prior surgical procedures were compared between patients with and without treatment failure.
Failure cases were more likely to have strictures following urethroplasty (21/27, 78%) [. the no-failure group (27/53, 51%)]. Among the 27/80 (33.8%) failures with a median follow-up of 8.4 months (IQR, 3.9-22.5 months), median time to recurrence was 4 months (IQR, 2-12 months). These patients had a greater incidence of prior stricture intervention in general (P=0.01) and prior urethroplasty specifically (P=0.03). On multivariable analysis, the number of prior treatments specifically independently remained associated with treatment failure. Complications of balloon dilation were uncommon (6/80, 7.5%) and minor in nature.
Endoscopic balloon dilation performs poorly as a salvage strategy after failed open urethral reconstruction in addition to prior urethral dilations.
尿道成形术后复发性尿道狭窄疾病(USD)的最佳管理策略仍不明确。我们旨在评估内镜下尿道球囊扩张术在尿道成形术失败后临时处理复发性USD中的作用和疗效。
2007年至2018年期间,在我们机构,80例患者因球部尿道膜部狭窄接受了球囊扩张手术。在16F可弯曲膀胱镜直视引导下,使用8cm、24F的UroMax Ultra™球囊扩张器进行球囊扩张。排除同期接受开放性或内镜下尿道手术的患者。治疗失败定义为因狭窄复发而需要后续手术干预。比较有治疗失败和无治疗失败患者的狭窄特征,包括病因、长度、位置、严重程度分期和既往手术情况。
失败病例更可能在尿道成形术后出现狭窄(21/27,78%),而无失败组为(27/53,51%)。在27/80(33.8%)例失败患者中,中位随访时间为8.4个月(四分位间距,3.9 - 22.5个月),复发的中位时间为4个月(四分位间距,2 - 12个月)。总体而言,这些患者既往狭窄干预的发生率更高(P = 0.01),尤其是既往尿道成形术(P = 0.03)。多变量分析显示,既往治疗的次数单独与治疗失败独立相关。球囊扩张的并发症不常见(6/80,7.5%)且性质轻微。
除既往尿道扩张外,内镜下球囊扩张作为开放性尿道重建失败后的挽救策略效果不佳。